

March 23, 2026  
KYORIN Pharmaceutical Co., Ltd.  
UBE Corporation

## **KYORIN and UBE Enter into License Agreement for Novel Drug Candidates**

---

KYORIN Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Yutaka Ogihara, hereinafter, "KYORIN") and UBE Corporation (Head Office: Minato-ku, Tokyo; President: Yuki Nishida, hereinafter, "UBE") announce that they have entered into a license agreement for novel drug candidates discovered by UBE.

Under the terms of this agreement, KYORIN has obtained exclusive worldwide rights to develop, manufacture, and commercialize these candidates. Accordingly, KYORIN will make an upfront payment to UBE. In addition, UBE is also eligible to receive development milestone payments based on the progress of development and approval, and commercial milestone payments upon the achievement of specific net sales targets. UBE will also receive royalties based on net sales.

KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain, autoimmune disorders, and neuromuscular disease as its key strategic therapeutic areas for research and development. Meanwhile, UBE creates lead compounds based on compound designs backed by its advanced organic synthesis capabilities.

Through this agreement, by integrating the creative compounds generated by UBE with KYORIN's research and development expertise, both companies aim to deliver new treatment options as early as possible to patients for whom existing drugs do not provide sufficient relief.

### **■About KYORIN**

KYORIN operates under the corporate philosophy, "KYORIN continues to fulfil its mission of cherishing life and benefiting society by contributing to better health." Based on this principle, we aim to continuously provide high-value new drugs that meet medical needs, striving to become a company that contributes broadly to people's health. In drug discovery, we focus our research efforts on the therapeutic areas of pain and autoimmune disorders and neuromuscular disease, working to create innovative new drugs that meet significant medical needs. In sales, we implement a Franchise Customer (FC) strategy, concentrating our resources on specialized areas, respiratory, otolaryngology, and urology.

<https://www.kyorin-pharm.co.jp/en/>

### **■About UBE**

UBE Corporation encompasses a group of specialty chemicals businesses, of which the pharmaceuticals business comprises the core of its life sciences portfolio, progressing beyond its track record of discoveries in small molecule therapeutics into high added-value products such as ADCs (antibody-drug conjugates). Alongside is a CDMO (contract development and manufacturing organization) business, which is strengthening its existing small molecule production capacity while also acquiring capabilities in novel modalities such as oligonucleotide therapeutics. UBE's life science businesses will continue to offer solutions that enhance and protect human life and health.

<https://www.ube.com/ube/en/>

---

### **For inquiries please contact:**

Corporate Planning, KYORIN Pharmaceutical Co., Ltd.  
Phone: +81-3-6374-9702

Public Relations Group, Corporate Communication Department, UBE Corporation  
Phone: +81-3-5419-6110 E-mail: [contact\\_pr@ube.com](mailto:contact_pr@ube.com)